ACE-031 and YK-11 Interaction: Monitor | Peptide Database

Research Use Only. Not for human use. All content on this page relates strictly to preclinical and in vitro research findings. ACE-031 — the fusion protein combining the extracellular domain of ActRIIB (Activin Receptor Type IIB) with human IgG1 Fc — is primarily recognised in research contexts as a myostatin and activin ligand trap with potent muscle-anabolic effects. However, the biology of the ActRIIB-ligand system extends substantially beyond skeletal muscle into bone metabolism, where the same ligands — myostatin (GDF-8), activin A, GDF-11 and BMP9 — regulate osteoblast and osteoclast activity with important implications for bone density and fracture biology. This post examines the mechanistic connections between ActRIIB ligand trapping, skeletal remodelling and osteoporosis research.

ACE-031’s neutralisation of activin A has direct anti-resorptive consequences through the osteoblast RANKL-OPG axis. Activin A (via ActRIIA/ALK-4/Smad2/3) upregulates RANKL expression in osteoblasts and suppresses OPG secretion, shifting the RANKL:OPG ratio toward net osteoclastogenesis. ACE-031 (which traps activin A) restores the RANKL:OPG balance: osteoblast conditioned media from activin A-treated ± ACE-031 cultures applied to RAW264.7 or primary BMDM osteoclast precursors demonstrates dose-dependent TRAP+ multinucleated osteoclast reduction. RANKL:OPG molar ratio (ELISA, R&D Systems DY805 sRANKL and DY805B OPG) in conditioned media is the primary mechanistic readout; serum RANKL and OPG as translational in vivo biomarkers at weekly intervals in OVX ± ACE-031 cohorts. Direct osteoclast ActRIIB expression: primary osteoclast precursors (BMDM, M-CSF 25 ng/mL 3d) and mature osteoclasts (RANKL 50 ng/mL + M-CSF 7-10d) express ActRIIB (RT-PCR, anti-ActRIIB antibody, R&D AF339). Myostatin and activin A direct stimulation of mature TRAP+ osteoclasts (pit resorption area on bovine bone slices, Osteoassay surface, μm², SEM or Osteo Assay fluorescent) establishes an ActRIIB-direct osteoclast stimulation mechanism fully abrogated by ACE-031 pre-incubation. This direct osteoclast RANKL-independent resorption pathway represents an additional bone resorption mechanism uniquely addressed by ActRIIB decoy receptor approach versus other anti-resorptive strategies.